Oruka Therapeutics(NASDAQ) ORKA

Oruka helps people with chronic skin diseases like psoriasis. It makes proteins that stop the body from attacking healthy skin. These injections aim to work with just one dose every year.

New Tools for Clear Skin

• ORKA-001: Injectable protein treatment that blocks the IL-23p19 pathway to clear psoriasis; designed for dosing as infrequently as once or twice annually.
• ORKA-002: Dual-acting antibody targeting two proteins that cause inflammation in the skin and joints; currently in trials for psoriasis and painful skin nodules.
• ORKA-021: Sequential treatment plan that combines two medicines to provide fast relief followed by long-lasting skin maintenance.
• ORKA-003: Research program focused on an undisclosed biological pathway for additional inflammatory skin conditions.

Making Big Strategic Moves

• Completed a merger with ARCA biopharma, Inc. in August 2024 to become a publicly traded company.
• Secured exclusive worldwide rights to develop and sell core programs through agreements with Paragon Therapeutics.
• Licensed essential manufacturing technology from WuXi Biologics in March 2024 to support clinical product development.
• Commenced dosing in the EVERLAST-A Phase 2a clinical trial for psoriasis in the third quarter of 2025.

Engineering for the Long Term

Oruka uses specialized engineering to make medicines stay in the body for several months. This allows patients to manage chronic conditions with fewer hospital visits and fewer annual injections.

Tracking the Financial Progress

• Operating income was a loss of $34.4 million in Q4 2025, up 10.2% from the previous year.
• Net loss reached $29.6 million in Q4 2025, an 11.4% improvement year-over-year.
• Market capitalization hit $1.6 billion in Q4 2025, up 406.7% from the prior year.
• Free cash flow was negative $22.7 million in Q4 2025, down 20.3% from Q4 2024.
• Total full-time workforce reached 28 employees by the end of the 2025 fiscal period.

The Final Word

Oruka is focusing on making current medical treatments more convenient for patients by extending how long they last in the body. The company is evolving from a research startup into a clinical-stage organization with multiple programs in human trials.